XIST como modulador da resistência à quimioterapia em cânceres
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Dec 19, 2024
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: O presente estudo buscou sumarizar as principais evidências que destacam o XIST como modulador da resistência à quimioterapia em diferentes tipos tumorais. Métodos: Para tanto, foi realizado levantamento bibliográfico, selecionando estudos que correlacionam XIST com a resistência a drogas antineoplásicas. Utilizou-se ferramentas bioinformáticas, incluindo NcPathName para identificar genes alvo e a plataforma CIViC para associar esses genes com a quimiorresistência, o papel de XIST foi investigado em diferentes tipos de câncer. Resultados: XIST regula genes associados à resistência quimioterápica, como PTEN, CDKN1A, CFLAR, MDM2 e ZEB1, envolvidos em vias essenciais de quimiorresistência. A interação entre XIST e esses genes sugere mecanismos moleculares específicos por trás da resistência a agentes como o 5-fluorouracil, no câncer colorretal. A literatura sugere que o knockdown de XIST pode ser uma estratégia promissora para superar a resistência à quimioterapia. Considerações finais: Este estudo evidencia a importância de explorar lncRNAs como XIST para entender melhor os mecanismos de resistência à quimioterapia e desenvolver abordagens terapêuticas mais eficazes.
##plugins.themes.bootstrap3.article.details##
Como Citar
BarbosaE. da S., SousaL. R. de, PalmeiraA. C. da C., MatosA. G. de M., OliveiraR. da S. de, MendonçaR. G., AlvesM. S., FonsecaS. S. S. da, TeixeiraE. B., & PinhoJ. D. (2024). XIST como modulador da resistência à quimioterapia em cânceres. Revista Eletrônica Acervo Saúde, 24(12), e17830. https://doi.org/10.25248/reas.e17830.2024
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. CORREA RG, et al. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep, 2012; 32(6): 597-608.
2. DEB G, et al. EZH2: Not EZHY (Easy) to Deal. Mol Cancer Res, 2014; 12(5): 639-53.
3 DU P, et al. LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep, 2017; 37(5): BSR20170696.
4. DUAN A, et al. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. J Oncol, 2022; 2022: 4537343.
5. FANG X, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis, 2020; 11(7): 531.
6. FUCHS RP, et al. Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide. Elife, 2021; 10: 69544.
7. GAO C, et al. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat, 2019; 176(2): 291-301.
8. HUA G, et al. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3. Pharmacology, 2021; 106(9-10): 498-508.
9. KUANG Y, et al. The role of lncRNA just proximal to XIST (JPX) in human disease phenotypes and RNA methylation: The novel biomarker and therapeutic target potential. Biomed Pharmacother, 2022; 155: 113753.
10. LAVOIE H, et al. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol, 2020; 21(10): 607-32.
11. LI Z, et al. Knockdown de lncRNA-HOTAIR downregula a resistência a drogas de células de câncer de mama à doxorrubicina através da via de sinalização PI3K/AKT/mTOR. Exp Ther Med, 2019; 18: 435-42.
12. LIU TT, et al. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network. Int J Med Sci, 2021; 18(2): 419-31.
13. LUO Y, et al. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy, 2021; 17(12): 4083-4101.
14. MA L, et al. Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget, 2017; 8(3): 4125-35.
15. MAHESH AN, et al. Cell cycle. Encyclopedia of Toxicology (Fourth Edition), 2023; 2: 667-674.
16. MENCK K, et al. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells, 2021; 10(1): 142.
17. OLA MS, et al. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem, 2011; 351(1-2): 41-58.
18. PENG Y, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol, 2022; 12.
19. ROY M e MUKHERJEE S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac J Cancer Prev, 2014; 15(3): 1403-10.
20. SÁNCHEZ-TILLÓ E, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ, 2014; 21(2): 247-57.
21. SCHOUTEN PC, et al. High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. Mol Cancer Ther, 2016; 15(1): 190-8.
22. SETHY C e KUNDU CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother, 2021; 137: 111285.
23. SHORNING BY, et al. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci, 2020; 21(12): 4507.
24. SIEGEL RL, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023; 73(1): 17-48.
25. SUN J, et al. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle, 2017; 16(21): 2100-7.
26. SUN W, et al. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep, 2017; 38(6): 3347-54.
27. TIAN LJ, et al. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Med Sci Monit, 2019; 25: 8095-104.
28. WANG H, et al. Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-L expressions in human nasopharyngeal carcinoma HNE1 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao, 2019; 39(3): 357-63.
29. XIA X, et al. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis. J Gynecol Oncol, 2022; 33(6).
30. XIAO Y, et al. Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. Oncotarget, 2017; 8(47): 83171-82.
31. XU X, et al. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging (Albany NY), 2020; 12(6): 4711-26.
32. YAO J, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol, 2017; 143(3): 419-31.
33. YAROMINA A, et al. Treatment modalities in cancer: An overview. Med Oncol (Northwood Lond Engl), 2020; 37(6): 52.
34. ZAFAR A, et al. MDM2- an indispensable player in tumorigenesis. Mol Biol Rep, 2023; 50(8): 6871-83.
35. ZHANG H, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer, 2020; 19(1): 43.
36. ZHANG M, et al. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin Exp Pharmacol Physiol, 2020; 47(8): 1464-72.
37. ZHANG R, et al. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J Cell Mol Med, 2019; 23(5): 3151-65.
38. ZHANG Z, et al. Autophagy/ferroptosis in colorectal cancer: Carcinogenic view and nanoparticle-mediated cell death regulation. Environ Res, 2023; 238(2):117006.
39. ZHENG H, et al. LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark, 2021; 30(4): 395-406.
40. ZHENG HX, et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene, 2013; 32(9): 1183-92.
2. DEB G, et al. EZH2: Not EZHY (Easy) to Deal. Mol Cancer Res, 2014; 12(5): 639-53.
3 DU P, et al. LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep, 2017; 37(5): BSR20170696.
4. DUAN A, et al. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. J Oncol, 2022; 2022: 4537343.
5. FANG X, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis, 2020; 11(7): 531.
6. FUCHS RP, et al. Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide. Elife, 2021; 10: 69544.
7. GAO C, et al. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat, 2019; 176(2): 291-301.
8. HUA G, et al. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3. Pharmacology, 2021; 106(9-10): 498-508.
9. KUANG Y, et al. The role of lncRNA just proximal to XIST (JPX) in human disease phenotypes and RNA methylation: The novel biomarker and therapeutic target potential. Biomed Pharmacother, 2022; 155: 113753.
10. LAVOIE H, et al. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol, 2020; 21(10): 607-32.
11. LI Z, et al. Knockdown de lncRNA-HOTAIR downregula a resistência a drogas de células de câncer de mama à doxorrubicina através da via de sinalização PI3K/AKT/mTOR. Exp Ther Med, 2019; 18: 435-42.
12. LIU TT, et al. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network. Int J Med Sci, 2021; 18(2): 419-31.
13. LUO Y, et al. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy, 2021; 17(12): 4083-4101.
14. MA L, et al. Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget, 2017; 8(3): 4125-35.
15. MAHESH AN, et al. Cell cycle. Encyclopedia of Toxicology (Fourth Edition), 2023; 2: 667-674.
16. MENCK K, et al. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells, 2021; 10(1): 142.
17. OLA MS, et al. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem, 2011; 351(1-2): 41-58.
18. PENG Y, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol, 2022; 12.
19. ROY M e MUKHERJEE S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac J Cancer Prev, 2014; 15(3): 1403-10.
20. SÁNCHEZ-TILLÓ E, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ, 2014; 21(2): 247-57.
21. SCHOUTEN PC, et al. High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. Mol Cancer Ther, 2016; 15(1): 190-8.
22. SETHY C e KUNDU CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother, 2021; 137: 111285.
23. SHORNING BY, et al. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci, 2020; 21(12): 4507.
24. SIEGEL RL, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023; 73(1): 17-48.
25. SUN J, et al. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle, 2017; 16(21): 2100-7.
26. SUN W, et al. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep, 2017; 38(6): 3347-54.
27. TIAN LJ, et al. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Med Sci Monit, 2019; 25: 8095-104.
28. WANG H, et al. Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-L expressions in human nasopharyngeal carcinoma HNE1 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao, 2019; 39(3): 357-63.
29. XIA X, et al. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis. J Gynecol Oncol, 2022; 33(6).
30. XIAO Y, et al. Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. Oncotarget, 2017; 8(47): 83171-82.
31. XU X, et al. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging (Albany NY), 2020; 12(6): 4711-26.
32. YAO J, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol, 2017; 143(3): 419-31.
33. YAROMINA A, et al. Treatment modalities in cancer: An overview. Med Oncol (Northwood Lond Engl), 2020; 37(6): 52.
34. ZAFAR A, et al. MDM2- an indispensable player in tumorigenesis. Mol Biol Rep, 2023; 50(8): 6871-83.
35. ZHANG H, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer, 2020; 19(1): 43.
36. ZHANG M, et al. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin Exp Pharmacol Physiol, 2020; 47(8): 1464-72.
37. ZHANG R, et al. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J Cell Mol Med, 2019; 23(5): 3151-65.
38. ZHANG Z, et al. Autophagy/ferroptosis in colorectal cancer: Carcinogenic view and nanoparticle-mediated cell death regulation. Environ Res, 2023; 238(2):117006.
39. ZHENG H, et al. LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark, 2021; 30(4): 395-406.
40. ZHENG HX, et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene, 2013; 32(9): 1183-92.